Please assess the completion status of the following clinical trial:

Trial Title: The Study Will Evaluate the Efficacy of AZD5423 in Patients With Mild Asthma Challenged With an Inhaled Allergen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* 18-60 years of age~* Pre-bronchodilatory FEV1 ≥70% of predicted normal allergic asthmatic with a history of episodic wheeze~* Positive allergen induced early and late airway bronchoconstriction showing ≥ 20% fall in FEV1 for the early and ≥ 15% for the late response~* Positive skin prick test to common aeroallergens~Exclusion Criteria:~* Any clinically significant disease or disorder~* Any clinically relevant abnormal finding at screening examinations~* Smoker or ex-smoker who has stopped smoking \< 12 months prior to study start~* Worsening of asthma or respiratory infection within 6 weeks from visit 1~* Allergen-specific immunotherapy within 6 months prior to visit 1

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): AZD5423 75ug
- 2 (Type: EXPERIMENTAL): AZD5423 300ug
- 3 (Type: ACTIVE_COMPARATOR): Budesonide 200 microgram
- 4 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).